# Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

* The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options.
* Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial.
* LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy.
* Lantern’s AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets.
* Additional trial data from Taiwan and the U.S. is expected later in Q3 2025.

 Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (“NSCLC”) patients (https://ibn.fm/JXFqG).

 The company enrolled 10 patients across five sites in Japan, including the National Cancer Center in Tokyo, ahead of its internal timeline. The milestone underscores Lantern Pharma’s international strategy to focus on regions with a higher prevalence of never-smoker NSCLC cases, an under-addressed…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/lantern-pharma-inc-nasdaq-ltrn-completes-japanese-enrollment-for-lp-300-phase-2-harmonictm-trial-ahead-of-schedule/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/lantern-pharma-advances-lp-300-trial-for-never-smoker-nsclc-in-japan/67886a3dd7b5d7cf4b344e94fe0384b3) 


Pickup - [https://burstable.news/news](https://burstable.news/news/202508/140264-lantern-pharma-inc-completes-japanese-enrollment-for-lp-300-phase-2-harmonic-tm-trial-ahead-of-schedule)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202508/140277-lantern-pharma-inc-completa-con-anticipacion-la-inscripcion-en-japon-para-el-ensayo-de-fase-2-harmonic-tm-de-lp-300)

Pickup - [https://platzennachrichten.de](https://platzennachrichten.de/202508/140324-lantern-pharma-inc-completa-con-anticipacion-el-reclutamiento-en-japon-para-el-ensayo-de-fase-2-harmonic-tm-de-lp-300)

Pickup - [https://actueclair.com](https://actueclair.com/202508/140317-lantern-pharma-inc-completa-con-antelacion-la-inscripcion-en-japon-para-el-ensayo-de-fase-2-harmonic-tm-de-lp-300)
 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1mk8s9q/lantern_pharma_advances_lp300_trial_for/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/258/7/pearIW_9.webp)